Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Morel

Showing results (91-100 of 156) with videos related to

Pageof 16
Sort By:
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
ACS Macro Letters|June 2, 2022
Measurement of Cohesion and Adhesion of Semiconducting Polymers by Scratch Testing: Effect of Side-Chain Length and Degree of PolymerizationDaniel Rodriquez, James G Kohl, Pierre Morel, et al.
Blood|November 23, 2016
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsMaria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, et al.
Ejhaem|March 20, 2025
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 9, 2023
Spatial Transcriptomics Reveal Pitfalls and Opportunities for the Detection of Rare High-Plasticity Breast Cancer SubtypesAngèle Coutant, Vincent Cockenpot, Lauriane Muller, et al.
British Journal of Haematology|November 3, 2021
Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometryValentin Clichet, Véronique Harrivel, Caroline Delette, et al.
Blood Advances|May 7, 2021
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Charles Herbaux, et al.
Journal of Neural Engineering|December 9, 2015
Long-term decoding of movement force and direction with a wireless myoelectric implantPierre Morel, Enrico Ferrea, Bahareh Taghizadeh-Sarshouri, et al.
Blood|November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaSteven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Pageof 16

Showing results (91-100 of 156) with videos related to

Sort By:
Pageof 16
Blood|September 6, 2013
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Meletios A Dimopoulos, Ramón García-Sanz, Maria Gavriatopoulou, et al.
ACS Macro Letters|June 2, 2022
Measurement of Cohesion and Adhesion of Semiconducting Polymers by Scratch Testing: Effect of Side-Chain Length and Degree of PolymerizationDaniel Rodriquez, James G Kohl, Pierre Morel, et al.
Blood|November 23, 2016
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 yearsMaria Gavriatopoulou, Ramón García-Sanz, Efstathios Kastritis, et al.
Ejhaem|March 20, 2025
Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World AnalysisThomas Hueso, Grégory Lazarian, Paul Chauvet, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 9, 2023
Spatial Transcriptomics Reveal Pitfalls and Opportunities for the Detection of Rare High-Plasticity Breast Cancer SubtypesAngèle Coutant, Vincent Cockenpot, Lauriane Muller, et al.
British Journal of Haematology|November 3, 2021
Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometryValentin Clichet, Véronique Harrivel, Caroline Delette, et al.
Blood Advances|May 7, 2021
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemiaCécile Tomowiak, Stéphanie Poulain, Charles Herbaux, et al.
Journal of Neural Engineering|December 9, 2015
Long-term decoding of movement force and direction with a wireless myoelectric implantPierre Morel, Enrico Ferrea, Bahareh Taghizadeh-Sarshouri, et al.
Blood|November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaSteven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
Blood|February 7, 2009
International prognostic scoring system for Waldenstrom macroglobulinemiaPierre Morel, Alain Duhamel, Paolo Gobbi, et al.
Pageof 16